Anmeldung beendet
Info
Downstream process development of therapeutic monoclonal antibodies is done with two primary goals in mind: High Yields and High Purity. However yield and purity are often in conflict when designing and optimizing a process. This presentation will discuss why that is often the case and how this can be approached when designing an industrial mAb purification process.
